Skip to Content
 
 
 
 

NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438)(IND #138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistnet Endometrioid Endometrial Adenocarcinoma

Objective

Clinical Trial Details >>

Principal Investigator(s)
David Starks, MD

Clinical Trial Categories

  • Gynecologic Cancer
Contact
Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.